Funding
Total seed financing · Biotech

Acta announces $24m in total seed funding for Alzheimer’s programs

The Boston biotech is advancing an oral drug candidate and combination therapies.

By RoundOS Funding desk

Acta Pharmaceuticals announced $24 million in total seed financing on October 15 to support therapies intended for earlier intervention in Alzheimer’s disease.

Its lead candidate, GSM-779690T, is entering a phase 1 program evaluating safety, tolerability and pharmacokinetics. Acta also has a combination-therapy program based on licensed Massachusetts General Hospital research.

Funding history

Total seed financing · This round$24M

Sources

  1. Acta Pharmaceuticals financing announcementactapharmaceuticals.com · Oct 15, 2026

Similar rounds

All Biotech rounds →
Estuary Biotherapeutics

Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.

$93MSeries A · Oct 16, 2026
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C · Oct 15, 2026
Silvia Bio

Cell profiling and media additives for more predictable biopharmaceutical manufacturing.

£3MSeed · Oct 15, 2026
Undecimal Bio

Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease.

$18MSeed · Oct 13, 2026

Related